Clinical overview of mesna.
Mesna is superior to standard prophylaxis in inhibiting the urotoxicity of oxazaphosphorines. Mesna does not interfere with the antitumour effect of oxazaphosphorines and other cytostatics. Mesna is well tolerated. Mesna can be given orally. Mesna should be administered with each ifosfamide treatment and with high dose cyclophosphamide. It should also be given to any patient who may be at risk of developing cystitis following oxazaphosphorine treatment.
D002986:Clinical Trials as Topic; D003520:Cyclophosphamide / Q000009:adverse effects; D004347:Drug Interactions; D006417:Hematuria / Q000139:chemically induced / Q000517:prevention & control; D006801:Humans; D007069:Ifosfamide / Q000009:adverse effects; D008623:Mercaptoethanol / Q000031:analogs & derivatives*; D015080:Mesna / Q000008:administration & dosage / Q000627:therapeutic use*; D009369:Neoplasms / Q000188:drug therapy*
D008623:Mercaptoethanol; D003520:Cyclophosphamide; D015080:Mesna; D007069:Ifosfamide